• Oct 5, 2026

  $27.41-1.40%

  Pfizer closed down 1.40%, and comparable pharmaceutical companies moved -0.80% on average that session, with 4 of 6 falling [1]. The decline was somewhat larger than the cohort average, and the peers were split, with BMY down 3.83% and MRK down 3.30% while ABT rose 2.67% [1]. The other items were opinion pieces or coverage of other companies, and none reported an event at Pfizer.

  • 1Peer group

• Oct 2, 2026

  $27.80-1.14%

  Pfizer shares fell 1.14% to 27.80. Seeking Alpha reported that Pfizer said phase 3 data supported Litfulo as a vitiligo treatment [1]. Seeking Alpha also reported that a Medicare drug pricing model would affect only four firms following Trump's MFN policy [2]. Neither item says why the shares fell.

  • 1Seeking Alpha
  • 2Seeking Alpha

• Oct 1, 2026

  $28.12-1.40%

  Comparable pharmaceutical companies fell 1.92% on average, with all 6 of 6 declining, so Pfizer's drop came alongside a move shared across the group [3]. Seeking Alpha reported that Florida's attorney general sued Pfizer over its COVID vaccine safety marketing [1]. Seeking Alpha also reported mid-stage trial results for a Pfizer eczema therapy [2].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Peer group

• Sep 30, 2026

  $28.52-0.70%

  Pfizer fell 0.70% while comparable pharmaceutical companies fell 0.97% on average, with 5 of 6 lower [1]. The move was broadly in line with that group, and the other headlines that day concerned the FDA, another company and an industry lobbying group rather than Pfizer.

  • 1Peer group

• Sep 29, 2026

  $28.72+0.00%

• Sep 28, 2026

  $28.72+0.17%

  Shares closed up 0.17%. Seeking Alpha reported that a Delaware judge let Monsanto's mRNA patent lawsuits against Pfizer, BioNTech and Moderna proceed, dealing the companies a blow in their effort to have the suits dismissed [1].

  • 1Seeking Alpha

• Sep 25, 2026

  $28.67+0.92%

Closing prices for PFE. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.